Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice
G Tiegs, J Barsig, B Matiba, S Uhlig, A Wendel, G Tiegs, J Barsig, B Matiba, S Uhlig, A Wendel
Abstract
GM-CSF is known to prime leukocytes for inflammatory stimuli in vitro. The objective of this study was to investigate the role of GM-CSF in vivo in a systemic inflammatory reaction syndrome. The results demonstrate a potentiation of LPS toxicity by GM-CSF in a mortality model as well as in a septic liver failure model in mice. Pretreatment of animals with 50 micrograms/kg GM-CSF induced lethality within 24 h in mice challenged with a subtoxic dose of LPS while controls survived > 72 h. A monoclonal anti-GM-CSF antibody significantly protected against a lethal LPS dose. Serum GM-CSF was inducible by LPS and peaked at 2 h. GM-CSF pretreatment dramatically potentiated systemic TNF release and hepatotoxicity induced by a subtoxic dose of LPS in galactosamine-sensitized mice. Potentiation of LPS hepatotoxicity was possible until 30 min after LPS challenge. Polyclonal anti-GM-CSF IgG protected against septic liver failure in this model and attenuated serum TNF concentrations. In vitro an ex vivo experiments revealed that after GM-CSF pretreatment LPS-induced IL-1 release from bone marrow or spleen cells was also enhanced. These findings suggest that GM-CSF represents an endogenous enhancer of LPS-induced organ injury, possibly by potentiating the release of proinflammatory cytokines such as TNF and IL-1.
References
- Hoppe Seylers Z Physiol Chem. 1971 Mar;352(3):412-8
- Annu Rev Immunol. 1991;9:159-91
- Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939-43
- Blood. 1980 Dec;56(6):947-58
- Science. 1985 Aug 30;229(4716):869-71
- J Clin Invest. 1986 Aug;78(2):597-601
- J Immunol Methods. 1986 Dec 4;95(1):99-105
- Cytokine. 1991 Sep;3(5):366-71
- Ann Surg. 1992 Apr;215(4):356-62
- Infect Immun. 1992 May;60(5):1994-2001
- Blood Rev. 1992 Mar;6(1):43-57
- N Engl J Med. 1992 Jul 2;327(1):28-35
- N Engl J Med. 1992 Jul 9;327(2):99-106
- J Immunol. 1992 Aug 1;149(3):918-24
- Ann Surg. 1992 Aug;216(2):117-34
- Immunol Rev. 1992 Jun;127:119-46
- FEMS Microbiol Immunol. 1992 Aug;4(6):317-22
- J Infect Dis. 1992 Nov;166(5):1204-5
- Circ Shock. 1992 Oct;38(2):145-52
- J Exp Med. 1987 Mar 1;165(3):657-63
- EMBO J. 1987 Aug;6(8):2261-5
- J Immunol. 1987 Nov 15;139(10):3422-30
- J Immunol. 1988 Feb 1;140(3):837-9
- Blood. 1988 Mar;71(3):672-6
- J Immunol. 1988 Jun 15;140(12):4315-22
- Blood. 1988 Aug;72(2):691-7
- J Immunol. 1988 Dec 1;141(11):3882-8
- Blood. 1989 Jan;73(1):64-7
- Mol Cell Biol. 1988 Aug;8(8):3432-8
- Biochem Pharmacol. 1989 Feb 15;38(4):627-31
- N Engl J Med. 1989 Apr 6;320(14):939-40
- J Clin Invest. 1989 Apr;83(4):1308-12
- J Immunol Methods. 1989 Jun 21;120(2):271-6
- Trends Pharmacol Sci. 1989 Apr;10(4):154-9
- Hepatology. 1989 Nov;10(5):887-91
- Blood. 1990 May 1;75(9):1895-6
- Blood. 1990 May 15;75(10):2049-52
- J Immunol. 1990 Jul 15;145(2):576-84
- Trends Pharmacol Sci. 1990 Jul;11(7):285-9
- Biochem Pharmacol. 1990 Sep 15;40(6):1317-22
- Methods Enzymol. 1990;186:675-80
- Am J Pathol. 1991 Feb;138(2):395-402
- FASEB J. 1991 Mar 1;5(3):338-43
- J Exp Med. 1991 Apr 1;173(4):1029-32
- Cell Immunol. 1991 Jul;135(2):360-71
- Ann Intern Med. 1991 Sep 15;115(6):457-69
- Immunol Lett. 1991 May;28(2):121-6
- Infect Immun. 1991 Oct;59(10):3484-91
- Immunology. 1971 Sep;21(3):427-36
Source: PubMed